Aug. 20, 2019 Price forecast | 2 weeks: 3.94% | 1 month: 5.11% | 3 months: 4.54%

ENZ stock forecast

Our latest prediction for Enzo Biochem, Inc.'s stock price was made on the Aug. 20, 2019 when the stock price was at 3.14$.

In the short term (2weeks), ENZ's stock price should outperform the market by 3.94%. During that period the price should oscillate between -6.66% and +12.77%.

In the medium term (3months), ENZ's stock price should outperform the market by 4.54%. During that period the price should oscillate between -14.37% and +33.50%.

Create a solid portfolio with ENZ

Add ENZ to your portfolio and optimize it!

About Enzo Biochem, Inc.

Enzo Biochem, Inc. engages in the development, manufacture and sale of technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. It operates through the following segments: Enzo Clinical Laboratory Services, Enzo Life Sciences Products, and Enzo Therapeutics. The Enzo Clinical Laboratory Services segment includes clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences Products segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. The Enzo Therapeutics segment develops multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

At the moment the company generates 87M USD in revenues.

On its last earning announcement, the company reported a profit of 0.05$ per share.

The book value per share is 1.83$

Enzo Biochem, Inc. website

Three months stock forecastAug. 20, 2019


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
87M 32.90% -27M -31.40% 2M 0.05 - - 47M 1.83 6M -8M -2M